Breakthrough drug can cut chances of lung cancer returning by a third when used alongside chemotherapy and surgery...so why have NHS chiefs rejected it?

Durvalumab has been shown in trials to be effective at curing patients with the most common form of lung cancer when combined in the early stages of the disease alongside chemotherapy.

  Health   Sep 1, 2024   0   19  Add to Reading List
Breakthrough drug can cut chances of lung cancer returning by a third when used alongside chemotherapy and surgery...so why have NHS chiefs rejected it?

ARE YOU TIRED OF LOW SALES TODAY?

Connect to more customers on doacWeb

Post your business here..... from NGN1,000

WhatsApp: 09031633831

ARE YOU TIRED OF LOW SALES TODAY?

Connect to more customers on doacWeb

Post your business here..... from NGN1,000

WhatsApp: 09031633831

ARE YOU TIRED OF LOW SALES TODAY?

Connect to more customers on doacWeb

Post your business here..... from NGN1,000

WhatsApp: 09031633831

Durvalumab has been shown in trials to be effective at curing patients with the most common form of lung cancer when combined in the early stages of the disease alongside chemotherapy.
Read Original   

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow